Verified Hepatorenal Syndrome Reversal As A Robust Multi-Component Primary End Point: The CONFIRM Study Trial Design

Verified Hepatorenal Syndrome Reversal As A Robust Multi-Component Primary End Point: The CONFIRM Study Trial Design

Khurram Jamil,1 S Chris Pappas,2 Florence Wong,3 Arun J Sanyal4 1Department of Scientific Affairs, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA; 2Scientific Affairs, Orphan Therapeutics, Lebanon, NJ, USA; 3Department of Medicine, Division of Gastroenterology, University of Toronto, Toronto, ON,...

Full description

Bibliographic Details
Main Authors: Jamil K, Pappas SC, Wong F, Sanyal AJ
Format: Article
Language:English
Published: Dove Medical Press 2019-11-01
Series:Open Access Journal of Clinical Trials
Subjects:
acute kidney injury
end-stage liver disease
renal insufficiency
vasoconstrictor agents
vasopressin
Online Access:https://www.dovepress.com/verified-hepatorenal-syndrome-reversal-as-a-robust-multi-component-pri-peer-reviewed-article-OAJCT

Internet

https://www.dovepress.com/verified-hepatorenal-syndrome-reversal-as-a-robust-multi-component-pri-peer-reviewed-article-OAJCT

Similar Items